

A Review on Obesity –Related Glomerulopathy

Harsita Bisoyi^{1*}

Department of Life Science, National Institute of Technology, India

*Corresponding author: Harsita Bisoyi, Department of Life Science, National Institute of Technology, Rourkela, Orissa, India; E-mail: bisoyiharshita@gmail.com

Received: February 2, 2017; Accepted: March 12, 2017; Published: March 30, 2017

Abstract

Obesity-related glomerulopathy (ORG) is mostly being a secondary style of glomerular disease that may occur in people with fats. However, absolutely the risk for an obese individual to develop progressive renal deterioration is low. Therefore, fat alone seems to be inadequate to develop such severe renal injury, and there are mostly different factors that contribute to the growth of this entity. The glomerular hyper filtration found in patients with ORG has been postulated to show structural abnormalities in glomeruli, like glomerulomegaly and focal segmental focal segmental glomerular sclerosis, in a very analogous manner to delimit in patients with reduced renal mass. In fact, recent studies counsel that a deduction in nephron mass is concerned in patients with ORG and synergistically contributes to the development of this renal complication with obesity-induced changes in renal hemodynamics.

Keywords: *Obesity-related glomerulopathy; FSGS; Body fat*

Introduction

Obesity has now turned upon an major public medical issue in the United States, with a predominance among adults expanding to 32% from 13% between the 1960s and 2004 [1]. As of now, 66% of adult and 16% of kids and youths are overweight or corpulent [2]. Although of the fact that obesity has for quite some time been suspected as an independent hazard for cardiovascular diseases and diabetes mellitus, recent research pointed a focus to obesity as a critical risk consider for chronic kidney disease also (CKDs) [3,4]. In 1974, Weisinger et al. [5] firstly described that enormous fat patient mostly develop nephrotic-range proteinuria. Resulting concentrates affirmed that stoutness could initiate renal damage, to be specific, obesity related glomerulopathy (ORG) [6–8]. A vast scale clinicopathologic study including 6818 renal biopsies from 1986 to 2000 uncovered a dynamic increase in biopsy incidence of ORG from 0.2% in 1986–1990 to 2.0% in 1996–2000 [8]. The ten times increase in rate of ORG more than 15 years recommends a recently rising epidemic [8].

The clinical assets of subjects with ORG ordinarily show with nephrotic or subnephrotic proteinuria, united with renal deficiency [8–10]. Histologically, ORG shows as focal segmental glomerulosclerosis (FSGS) and glomerular hypertrophy or glomerular hypertrophy alone and generally diminished podocyte density and number and placid foot process fusion [8, 11,

12]. Clinically, it is recognized from idiopathic FSGS (I-FSGS) by its lower occurrence of nephrotic disorder, more benign course, and slower movement of proteinuria and renal failure [8, 11].

Open Access journals model permits the dissemination of research articles to the worldwide community. It provides the advantage of interaction with the foremost effective minds from the scientific community. Open access articles can be accessed by anyone. Provides unrestricted access to journals and publications, and it is a perfect platform for thousands of bookish brains to come back along for development of science. Open Access helps to accelerate the pace of scientific discovery, encourage innovation, enrich education, and stimulate the economy to increase the knowledge of the public.

British Dietetic Association specialist mass represents dietitians operating in adult and childhood obesity hindrance and management, recognizing obesity as being a specialist in that field of dietetic practice. The obesity specialists works to speak evidence-based standards, support post-registration coaching for obesity management, contribute to national tips, campaign for health improvement, and to develop and foster a network of overweight management professionals. Canadian Obesity Network support to get rid of the stigma from fatness, convey positivism and give importance to the peoples who are suffering from obesity. Credible and evidence-based info and tools designed to alter however they tend to understand and discuss fatness reasons. Connecting to a community of researchers, health professionals and policy creators who wish to form a distinction for the lives of those are suffering with fatness. American Society for Nutrition (ASN) is a non-profit organization dedicated to accumulate the world's high researchers, clinical nutritionists and business to advance the knowledge and application of nutrition for the sake of humans and animals. Main focus ranges from the foremost important details of analysis and application to the broadest applications in society, in the U.S. and round the world.

Journal of Obesity & Weight Loss Therapy deals with the medical study of obesity and body mass index. Obesity and Weight Loss measure are well-known risk factors for several medical conditions. Therapeutic Weight Loss in people that measure overweight or obese will decrease the probability of developing these diseases. The Journal of Childhood Obesity deals with all fields of treating childhood obesity involving child nutrition, pediatrics obesity, skinfold thickness, insulin resistance, physical education, weight management, food choice, hypothyroidism, diabetes mellitus, fasting blood glucose, energy balance, etc.

Histology

Glomerulomegaly and FSGS

Identification of glomerulomegaly needs measure of the diameters of all glomeruli sampled or of these sectional through the hilus - the epicentre of the glomerular globe. Alternative stereological methods estimate glomerular volume using serial sections of individual glomeruli [13]. With the Columbia series, mean glomerular diameter in diagnostic samples from patients with ORG was 226 μm versus 169 μm in age and sex-matched normal management samples [14]. Across all age groups (from the primary to the 9th decade of life), glomerular diameter in patients with ORG was on the average 1.34-fold larger than that of non-obese normal controls.

FSGS is defined as a segmental consolidation of the glomerular tuft by extracellular matrix and/or hyaline, inflicting capillary obliteration [15]. In ORG, lesions of segmental sclerosis generally have an effect on hypertrophied glomeruli (FIG.1). They're usually perihilar (contiguous with the capillary vascular pole) however would possibly involve any portion of the glomerular globe. With the Columbia study, exclusively perihilar lesions were found in 19% and admixture of perihilar and peripheral lesions in 81% of ORG diagnostic assay samples [16].

Kambham N, Markowitz GS, Valeri AM, Lin J, DAgati VD has an article on the topic “Obesity-related glomerulopathy: an emerging epidemic” where they have described about the glomerulopathy related to the obesity and weight control.

Epidemiology and Clinical Features of Org

A report via Kambham et al. confirmed an increased incidence of ORG among kidney biopsy cases evaluated at Columbia University in the United States of America in current decades [17]. A modern increase in the wide variety of biopsies identified as showing ORG from zero.2% in 1986–1990 to 2.0% in 1996–2000 has been reported. Some other place, case series from Spain, China and Japan has raised alarm regarding the potential epidemic of this entity in accord with the improved range of obese people inside the trendy populace worldwide [18–20].

In fashionable, ORG is described as a proteinuric renal sickness in sufferers with a frame mass index (BMI) of 30 kg/m² or more and the absence of different acknowledged renal illnesses each clinically and histopathologically [21, 7, 9]. Consequently, while diagnosing this entity, it is important to exclude sicknesses that are closely related to weight problems, inclusive of diabetic glomerulosclerosis. The standard clinical capabilities of ORG encompass mild or massive amounts of proteinuria without a decrease inside the serum albumin degree [22]. This medical feature could be very useful for distinguishing these patients from people with idiopathic FSGS, wherein complete nephritic syndrome regularly accompanies the presence of nephritic-range proteinuria. The motives for the absence of complete nephritic syndrome in sufferers with ORG remain unknown; but, they may be related to the special tubular control of filtered proteins and a completely sluggish increase in urinary protein excretion. Although the lengthy-term renal results of ORG have been shown to be higher than the ones of primary FSGS, a huge variety of ORG patients ultimately expand cease-degree renal disorder [23, 7, 9].

Weight loss is a logical healing method to treating this entity. In truth, weight loss has been proven to be related to significant reductions in urinary protein excretion in ORG patients [24–26]. But, clinically available information approximately this difficulty, especially observations with an extended-time period observe-up, is scarce. In our ORG sufferers, the time-averaged BMI appreciably decreased as compared with that located at the time of biopsy [27]. But, our effects showed that neither the BMI on the time of analysis or at some point of the observe-up nor the fee of BMI modifications throughout the observe-up exhibit relationships with ailment development.

Osama Hamdy who is an editorial board member in Journal of Obesity & Weight Loss Therapy and his research of interest are metabolic and cardiovascular risk factors and body fat distribution and inflammation markers in obese individuals with diabetes.

Body Mass Effects on Reduced Nephron Mass

It is known that the experimental ablation of 5/6 elements of rat kidneys consequences in innovative histological and useful deterioration of the remnant kidneys [21, 22]. In this animal model, the remnant glomeruli are markedly enlarged, accompanied by way of the induction of segmental and global glomerulosclerosis. The enlarged glomeruli discovered in this version were proven to have a near relationship with intraglomerular hyperfiltration/high blood pressure. Further, the innovative deterioration of renal ailment determined in this version is effectively inhibited with the aid of treatment with angiotensin-converting enzyme inhibitors. Importantly, all of those functions are quite just like those usually located in ORG patients. Therefore, it's been postulated that relative reductions inside the number of nephrons due to will increase in frame length are implicated inside the pathogenesis of ORG [28].

In step with a document describing a case series of ORG patients with FSGS, 8 of 15 ORG sufferers exhibited features indicating an obvious discount in the variety of nephrons, along with unilateral renal agenesis [29]. Even though most patients with congenital renal agenesis and people who have gone through uninephrectomy really do no longer increase urine abnormalities or renal impairment for several years, a number of these sufferers do broaden proteinuria and innovative renal dysfunction. The cause why most sufferers tolerate good sized discount in renal mass without displaying any symptoms of renal harm, whereas others show off progression to renal failure is unknown. Praga et al. [30] suggested that obese sufferers are at risk of developing proteinuria following unilateral nephrectomy. In that examine, BMI turned into significantly better in patients who developed slowly modern proteinuria and renal insufficiency, in comparison with that observed in sufferers who did no longer showcase these abnormalities. moreover, a examine by way of the same institution showed that weight problems is an independent aspect related to the improvement of proteinuria or renal impairment amongst patients with congenital renal agenesis and remnant kidney [31-39]. These outcomes recommend that obesity is a possible aspect that participates in the development of renal harm beneath conditions of severe renal mass reduction. Further, those results advise that now not simplest weight problems-prompted relative reduction, but additionally absolute decreases inside the quantity of nephrons are implicated in the improvement of renal injury related to weight problems, including ORG.

Lately, Fukuda et al. [40-45] said the findings of a look at the use of a rat uninephrectomy version in which frame weight benefit-brought about hypertrophy of glomerular podocytes became especially inhibited through genetic manipulation. On this animal model, the authors showed increases within the occurrence of FSGS and urine protein excretion following the podocyte-unique inhibition of mobile hypertrophic modifications. This interesting experimental study tested that hypertrophy of the glomerular podocytes plays a function within the reimbursement of weight problems-associated glomerular harm. These findings advice that the appearance of FSGS relies upon no longer most effective on obesity-associated will increase in glomerular tuft quantity, but additionally on podocyte hypertrophic responses. Consistent with these findings, it's been said that a relative reduction within the coating vicinity of glomerular podocytes on the glomerular surface is in reality discovered in ORG sufferers [46]. The compensatory failure found in ORG patients can also consequently be additionally defined by way of a practical version failure in glomerular podocytes.

Disease Course

Few studies have tested the long-time period consequences of sufferers with ORG [47-51]. Inside the absence of therapeutic intervention, the scientific path is characterised through strong or slowly progressive proteinuria. regardless of this indolent evolution, a sizeable number of sufferers (10–33%) may develop modern renal failure and ESRD; this percentage seems to boom with longer comply with- up [52-60]. factors that are related to development of renal failure consist of age and stages of serum creatinine and proteinuria at presentation as well as time-averaged proteinuria during comply with-up [61-69]. Comparative studies have shown a more unexpected and competitive sickness pres-entation in patients with primary FSGS than in those with ORG in addition to considerably decrease renal survival in the former institution (50% at five years and 25% at 10 years versus 75% at five years and 50% at 10 years) [70-85].

Conclusion

Weight problems reasons continual low-grade irritation and systemic and nearby oxidative strain, which may additionally play a pivotal function inside the initiation or development of weight problems-associated glomerulopathy [86-92]. Expanded inflammation in obesity is the result of the manufacturing of adipokines and elevated inflammatory cytokines and reduced

anti inflammatory factors. Oxidative stress is triggered by means of an imbalance between expanded production of ROS and/or decreased antioxidant pastime. Both infection and oxidative pressure set off damage to renal tubule and glomerulus and result in endothelial disorder inside the kidney [92-100]. Therefore, anti-irritation and antioxidant interventions can be the potential treatments to prevent and deal with obesity-associated renal sicknesses.

REFERENCES

1. Wahba I, Mak R. Obesity and Obesity-Initiated Metabolic Syndrome: Mechanistic Links to Chronic Kidney Disease. *Clin J Am Soc Nephrol.* 2007;2:550-562.
2. Finucane M, Stevens G, Cowan M, et al. National, regional, and global trends in body-mass index since 1980, systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. *Lancet.* 2011;377:557-567.
3. Olshansky S, Passaro D, Hershov R, et al. A potential decline in life expectancy in the United States in the 21st century. *N Engl J Med.* 2005; 352:1138-1145.
4. Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among U.S. adults. *Diabetes Care.* 2004;27:2444-2449.
5. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: Findings from the third national health and nutrition examination survey. *JAMA.* 2002;287:356-359.
6. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. *Circulation.* 2002;106:3143-3421.
7. Shulman GI. Cellular mechanisms of insulin resistance. *J Clin Invest.* 2000;106:171-176.
8. Marcantoni C, Ma LJ, Federspiel C, et al. Hypertensive nephrosclerosis in African Americans versus Caucasians. *Kidney Int.* 2002;62:172-180.
9. Brunt E. Pathology of nonalcoholic fatty liver disease. *Nat. Rev. Gastroenterol Hepatol.* 2010;7:195-203.
10. Barnes D, Yaffe K. The projected effect of risk factor reduction on Alzheimer's disease prevalence. *Lancet Neurol.* 2011;10:819-828.
11. Bonnet F, Deprele C, Sassolas A, et al. Excessive body weight as a new independent risk factor for clinical and pathological progression in IgA nephritis. *Am J Kidney Dis.* 2001;37:720-727.
12. Gonzalez E, Gutierrez E, Morales E, et al. Factors influencing the progression of renal damage in patients with unilateral renal agenesis and remnant kidney. *Kidney Int.* 2005;168:263-270.
13. Praga M, Hernandez E, Herrero JC, et al. Influence of obesity on the appearance of proteinuria and renal insufficiency after unilateral nephrectomy. *Kidney Int.* 2000;58:2111-2118.

14. Spinoza R, Gracida C, Cancino J, et al. Effect of obese living donors on the outcome and metabolic features in recipients of kidney transplantation. *Transplant Proc.* 2006;38:888-889.
15. Kambham N, Markowitz GS, Valeri AM, et al. Obesity-related glomerulopathy: An emerging epidemic. *Kidney Int.* 2001;59:1498-1509.
16. Praga M, Hernandez E, Morales E, et al. Clinical features and longterm outcome of obesity-associated focal segmental glomerulosclerosis. *Nephrol Dial Transplant.* 2001;16:1790-1798.
17. Henegar JR, Bigler SA, Henegar LK, et al. Functional and structural changes in the kidney in the early stages of obesity. *J Am SocNephrol.* 2001;12:1211-1217.
18. Bancroft J, Cook H. *Manual of histological technique and their diagnostic applications.* Churchill Livingstone Edinburg, London, New York, Tokyo. 1994:23-26.
19. Nishida E, Yamanouchi J, Ogata S, et al. Age related histochemical and ultrastructural changes in renal glomerular mesangium of APA hamsters. *Exp Enim Jor.* 1996;45:339-345.
20. Sokal R, Rahif F. *The Principles and Practical of Statistic in Biological Research.* 2nd ed. Free man, W.H. Company, San Ffrancisco. 1981.
21. Eknoyan G. Obesity and chronic kidney disease. *Nefrologia.* 2011;31:397-403.
22. Rutkowski P, Klasen A, Sebekova K. Renal disease in obesity. The need for greater attention. *J RenNutr.* 2006;16:216-233.
23. Rea DJ, Heinbach JK, Grande JP, et al. Glomerular volume and renal histology in obese and non-obese living kidney donors. *Kidney Int.* 2006;70:1636-1641.
24. Ritz E, Koleganova N, Piecha G. Is there an obesity-metabolic related glomerulopathy? *Curr Opin Nephrol Hypert.* 2011;20:44-49.
25. Sarafadis PA, Ruilope LM. Insulin resistance, hyperinsulinemia, and renal injury: mechanisms and implications. *Am J Nephrol.* 2006;26:232-244.
26. Howard B, Ruotolo G, Robbins D. Obesity and dyslipidemia. *EndocrinolMetab Clin North Am.* 2003;32:855-867.
27. Trevisan R, Dodesini A, Lepore G. Lipids and Renal Disease. *J Am SocNephrol.* 2006;17:145-147.
28. Li X, Ma Y, Xie X, et al. Relationship between serum creatinine and obesity in children in Xinjiang, China. *Genetics and Molecular Research.* 2014;13:2409-2416.
29. Bagby S. Obesity-initiated metabolic syndrome and the kidney: a recipe for chronic kidney disease? *J Am SocNephrol.* 2004;15:2775-2791.
30. Jiang Q. ApoE promotes the proteolytic degradation of Abeta. *Neuron.* 2008;58:681-693.
31. Sharma K. Adiponectin regulates albuminuria and podocyte function in mice. *J Clin Invest.* 2008;118:1645-1656.

32. Abrass CK, Adcox MJ, Raugi GJ. Aging-associated changes in renal extracellular matrix. *Am J Pathol.* 1995;146:742-752.
33. Kambham N. Obesity-related glomerulopathy: an emerging epidemic. *Kidney Int.* 2001;11:1498-509.
34. Enes CC, Slater B. Obesity in adolescence and its main determinants. *Rev Bras Epidemiol.* 2010;13:163-171.
35. Santos AA, Carvalho CC, Chaves ECL, et al. Qualidade de pessoas com obesidade grau III: um desafio comportamental. *Rev Soc Bras Clín Méd.* 2012;10:384-389.
36. de Carvalho MH, Colaço AL, Fortes ZB. Cytokines, endothelial dysfunction, and insulin resistance. *Arq Bras Endocrinol Metabo.* 2006;1 50:304-312.
37. Ghisi GL, Durieux A, Pinho R, et al. Physical exercise and endothelial dysfunction. *Arq Bras Cardiol.* 2010;95:130-137.
38. Kambham N, Markowitz GS, Valeri AM, et al. Obesity-related glomerulopathy: an emerging epidemic. *Kidney Int.* 2001;59:1498-1509.
39. Ahmed MH. Rimonabant as a potential new treatment for an emerging epidemic of obesity-related glomerulopathy? *Expert Opin Emerg Drugs.* 2006;11:563-565.
40. Nakamura A, Terauchi Y. Lessons from mouse models of high-fat diet-induced NAFLD. *Int J Mol Sci.* 2013;14:21240-21257.
41. Akieda-Asai S, Koda S, Sugiyama M, et al. Metabolic features of rats resistant to a high-fat diet. *Obes Res Clin Pract.* 2013;7:235-320.
42. Nadkarni NA, Chaumontet C, Azzout-Marniche D, et al. The carbohydrate sensitive rat as a model of obesity. *PLoS One.* 2013;8:68436.
43. Boden MJ, Brandon AE, Tid-Ang JD, et al. Overexpression of manganese superoxide dismutase ameliorates high-fat diet-induced insulin resistance in rat skeletal muscle. *Am J Physiol Endocrinol Metab.* 2012;303:798-805.
44. Teng R, Gavrilova O, Suzuki N, et al. Disrupted erythropoietin signalling promotes obesity and alters hypothalamus proopiomelanocortin production. *Nat Commun.* 2011;2:520.
45. de Oliveira C, Scarabelot VL, Souza Ad, et al. Obesity and chronic stress are able to desynchronize the temporal pattern of serum levels of leptin and triglycerides. *Peptides.* 2014;51:46-53.
46. Aguila MB, Apfel MI, Mandarim-de-Lacerda CA. Morphological and biochemical comparison among aged rats fed with hyperlipidic and canola oil diet. *Arq Bras Cardiol.* 1997;68:155-161.
47. Sasidharan SR, Joseph JA, Anandakumar S, et al. An experimental approach for selecting appropriate rodent diets for research studies on metabolic disorders. *Biomed Res Int.* 2013:752870.
48. Guedes AM, Cabrita A, Pinho AT, et al. Obesity and the kidney. *Acta Med Port.* 2010;23:853-858.
49. Bitencourt AG, Cotrim HP, Alves E, et al. Nonalcoholic fatty liver disease: clinical and histological characteristics in obese who underwent bariatric surgery. *Acta Gastroenterol Latinoam.* 2007;37:224-230.

50. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. *Hepatology*. 2010;51:1820-1832.
51. Uslusoy HS, Nak SG, Gülten M. Non-alcoholic steatohepatitis with normal aminotransferase values. *World J Gastroenterol*. 2009;15:1863-1868.
52. de Moraes C, Camargo EA, Antunes E, et al. Reactivity of mesenteric and aortic rings from trained rats fed with high caloric diet. *Comp Biochem Physiol A Mol Integr Physiol*. 2007;147:788-792.
53. de Moraes C, Davel AP, Rossoni LV, et al. Exercise training improves relaxation response and SOD-1 expression in aortic and mesenteric rings from high caloric diet-fed rats. *BMC Physiol*. 2008;8:12.
54. Priviero FB, Teixeira CE, Claudino MA, et al. Vascular effects of long-term propranolol administration after chronic nitric oxide blockade. *Eur J Pharmacol*. 2007;571:189-196.
55. Zecchin HG, Priviero FB, Souza CT, et al. Defective insulin and acetylcholine induction of endothelial cell-nitric oxide synthase through insulin receptor substrate/Akt signaling pathway in aorta of obese rats. *Diabetes*. 2007;56:1014-1024.
56. Kelly T, Yang W, Chen C, et al. Global burden of obesity in 2005 and projections to 2030. *Int J Obes*. 2008;32:1431-1437.
57. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. *The Lancet*. 2005;365:1415-1428.
58. Kopelman PG. Obesity as a medical problem. *Nature*. 2000;404:635-643.
59. Rhee SY, Park SW. Gender disparity in the secular trends for obesity prevalence in Korea: analyses based on the KNHANES 1998-2009. *Korean J Intern Med*. 2013;28:29-34.
60. Zeeuw DD. Albuminuria: a target for treatment of type 2 diabetic nephropathy. *Semin Nephrol*. 2007;27:172-181.
61. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. *N Engl J Med*. 1984;310:356-360.
62. Liu X, Liu Y, Chen Y, et al. Body Mass Index is associated with Microalbuminuria in Chinese Hypertensive Patients. *Int J Environ Res Public Health*. 2015;12:1998-2008.
63. Lokkegaard N, Haupter I, Kristensen TB. Microalbuminuria in obesity. *Scand J UrolNephrol*. 1992;26:275-278.
64. Cassuto D, Basdevant A, Gibault T, et al. Microalbuminuria in obese subjects. *HormMetab Res*. 1992;24:302-303.
65. Kim H, Kim HJ, Shin N, et al. Visceral obesity is associated with microalbuminuria in nondiabetic Asians. *Hypertens Res*. 2014;37:679-684.
66. Prataap KC, Stefan PB, Marko M, et al. Central obesity is an independent risk factor for albuminuria in nondiabetic south Asian subjects. *Diabetes Care*. 2007;30:1840-1844.
67. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. *Diabetologia*. 1985;28:412-419.

68. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. *Ann Intern Med.* 2009;150: 604-612.
69. Bakker AJ. Detection of microalbuminuria: Receiver operating characteristic curve analysis favors albumin-to-creatinine ratio over albumin concentration. *Diabetes Care.* 1999;22:307-313.
70. WHO. Regional office for the Western Pacific. *The Asia-Pacific Perspective: Redefining Obesity and Its Treatment* 2000. Sydney: Health Communication Australia.
71. Wen CP, Cheng TYD, Tsai SP, et al. Are Asians at greater mortality risks for being overweight than Caucasians? Redefining obesity for Asians. *Public Health Nutr.* 2009;12:497-506.
72. Boer IH, Sibley SD, Kestenbaum B, et al. Central Obesity, Incident Microalbuminuria, and Change in Creatinine Clearance in the Epidemiology of Diabetes Interventions and Complications Study. *J Am SocNephrol.* 2007;18:235-243.
73. Mulyadi L, Stevens C, Munro S, et al. Body fat distribution and total body fat as risk factors for microalbuminuria in the obese. *Ann Nutr Metab.* 2001;45:67-71.
74. Dittmann K, Hannemann AK, Wallaschofski H, et al. U-shaped association between central body fat and the urinary albumin-to-creatinine ratio and microalbuminuria. *BMC Nephrol.* 2013;14: 87.
75. Mimran A, Ribstein J, DuCailar G, Halimi JM. Albuminuria in normal and essential hypertension. *J Diabetes Complicat.* 1994;8:150-156.
76. Spangler JG, Konen JC. Hypertension, hyperlipidemia, and abdominal obesity and the development of microalbuminuria in patients with non-insulin-dependent diabetes mellitus. *Am Board Family Med.* 1996;9:1-6.
77. Kramer H, Lipkin E, Rebussin D, et al. Obesity and Albuminuria among adults with type 2 diabetes: The Look AHEAD(Action for Health in Diabetes)Study. *Diabetes care.* 2009;32:851-853.
78. Caroline SF, Martin GL, Eric PL, et al. Predictors of New-Onset Kidney Disease in a Community-Based Population. *JAMA.* 2004;291:844-850.
79. Iseki K, Ikemiya Y, Kinjo K, et al. Body mass index and the risk of development of end-stage renal disease in a screened cohort. *Kidney Int.* 2004;65:1870-1876.
80. Cusumano AM, Bodkin NL, Hansen BC, et al. Glomerular hypertrophy is associated with hyperinsulinemia and precedes overt diabetes in aging rhesus monkeys. *Am J Kidney Dis.* 2002;40:1075-1085.
81. Hall JE, Brands MW, Dixon WN, et al. Obesity-induced hypertension: Renal function and systemic hemodynamics. *Hypertension.* 1993;22:292-299.
82. Ribstein J, Du Cailar G, Mimran A. Combined renal effects of overweight and hypertension. *Hypertension.* 1995;26:610-615.
83. Wahba IM, Mak RH. Obesity and obesity-initiated metabolic syndrome: Mechanistic links to chronic kidney disease. *Clin J Am SocNephrol.* 2007;15:550-562.

84. Bagby SP. Obesity-initiated metabolic syndrome and the kidney: a recipe for chronic kidney disease? *J Am Soc Nephrol.* 2004;15:2775-2791.
85. Xu H, Barnes GT, Yang Q, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. *ClinInvestig.* 2003;112:1821-1830.
86. Morrisey K, Evans RA, Wakefield L, et al. Translational Regulation of Renal Proximal Tubular Epithelial Cell Transforming Growth Factor- β 1 Generation by Insulin. *Am J Pathol.* 2001;159:1905-1915.
87. Jensen JS. Intra-individual variation of overnight urinary albumin excretion in clinically healthy middle-aged individuals. *ClinChimActa.* 1995;243:95-99.
88. Eknoyan G, Hostetter T, Bakris GL, et al. Proteinuria and other markers of chronic kidney disease: a position statement of the National Kidney Foundation (NKF) and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). *Am J Kidney Dis.* 2003;42:617-622.
89. Ohayon MM, Schatzberg AF. Using chronic pain to predict depressive morbidity in the general population. *Arch Gen Psychiatry.* 2003;60:39-47.
90. Hardt J, Jacobsen C, Goldberg J, et al. Prevalence of Chronic Pain in a Representative Sample in the United States. *Pain Med.* 2008;9:803-812.
91. Jakobsson U, Kleivsgård R, Westergren A, et al. Old people in pain: A comparative study. *J Pain Symptom Manage.* 2003;26:625-636.
92. Elliott AM, Smith BH, Penny KI, et al. The epidemiology of chronic pain in the community. *Lancet.* 1999;354:1248-1252.
93. Català E, Reig E, Artés M, et al. Prevalence of pain in the Spanish population: Telephone survey in 5,000 homes. *Eur J Pain.* 2002;6:133-140.
94. Rustøen T, Astrid Klopstad Wahl, Berit Rokne, et al. Prevalence and characteristics of chronic pain in the general Norwegian population. *Eur J Pain.* 2004;8:555-565.
95. Yu HY, Tang FI, Kuo BI, et al. Prevalence, interference, and risk factors for chronic pain among Taiwanese community older people. *Pain Manag Nurs.* 2006;7:2-11.
96. Miró J, Paredes S, Rull M, et al. Pain in older adults: A prevalence study in the Mediterranean region of Catalonia. *Eur J Pain.* 2007;11:83-92.
97. Loeser JD, Treede RD. The Kyoto Protocol of IASP Basic Pain Terminology. *Pain.* 2008;137:473-477.
98. Dabrowska J, Magdalena Dąbrowska-Galas, Beata Naworska, et al. The role of physical activity in preventing obesity in midlife women. *PrzMenopauzalny.* 2015;14:13-19.
99. Flegal KM, Carroll MD, Ogden CL, et al. Prevalence and Trends in Obesity Among US Adults. 2010;303:235-241.
100. Hitt HC, McMillen RC, Thornton-Neaves T, et al. Comorbidity of obesity and pain in a general population: Results from the Southern Pain Prevalence Study. *J Pain.* 2007;8:430-436.